One of the original weekly GLP-1 injections, approved for type 2 diabetes and widely used off-label for weight loss. More modest results than newer options, but a decade of real world use and one of the most patient friendly devices on the market.
A once weekly GLP-1 injection approved for diabetes, with a decade of real world use and a simple autoinjector design.Trulicity is a once weekly subcutaneous injection approved for type 2 diabetes in 2014. It was one of the first weekly GLP-1 drugs on the market, giving it an unusually long safety and efficacy track record compared to most competitors.
Trulicity works by mimicking GLP-1, a hormone your body releases after eating that tells your brain you're full and slows digestion. It belongs to the same drug class as Ozempic, Wegovy, and Zepbound.
Where it stands out is ease of use. One click injects the dose, the needle never visibly extends, and patients who are nervous about injections often find it less intimidating than other pens. A drug you actually use every week beats a stronger one you skip.
The tradeoff is efficacy. Trulicity produces 5 to 8 percent weight loss on average, roughly half of Wegovy and less than a third of Zepbound. If max weight loss is the goal, stronger options exist. But if you have diabetes, want a simple weekly shot with a long track record, and your insurance covers it, Trulicity is a solid choice.
The Science, Simply
How Trulicity Works
GLP-1 activation reduces hunger, slows digestion, and improves blood sugar control, all from one weekly shot.Trulicity works by activating GLP-1 receptors throughout the body. It's a single pathway drug, unlike tirzepatide, but its effects are broad and clinically meaningful for both blood sugar and weight.
1
GLP-1 Activation: Hunger Reduction and Slower Digestion
Dulaglutide binds to GLP-1 receptors in the brain's appetite center, reducing the drive to eat. It also slows gastric emptying, so food stays in your stomach longer, which means you feel full sooner and stay satisfied for longer after meals. This is the primary mechanism behind its modest but consistent weight loss effect.
2
Improved Insulin Response and Blood Sugar Control
GLP-1 receptor activation in the pancreas stimulates insulin release in a glucose dependent way, meaning it only triggers insulin secretion when blood sugar is actually elevated. This is why hypoglycemia risk is low when Trulicity is used alone. It also suppresses glucagon, the hormone that raises blood sugar between meals, giving you more stable glycemic control throughout the day.
3
A Slow Titration Designed for Tolerability
Trulicity starts at 0.75 mg weekly for four weeks before moving to 1.5 mg, and can escalate further in four week intervals to 3 mg and then 4.5 mg. The slow ramp is intentional. It reduces the GI side effects that come with rapid dose escalation. The autoinjector mechanism also plays a role in tolerability: patients who don't have to watch a needle go in tend to follow through more consistently with each weekly dose.
Clinical Trial Data
What the AWARD Trials Showed
The AWARD program ran 9 trials comparing dulaglutide against placebo, insulin, and other GLP-1 drugs. Weight loss was a secondary endpoint.The AWARD (Assessment of Weekly AdministRation of dulaglutide) trial program enrolled thousands of type 2 diabetes patients across nine trials. Weight loss was a secondary endpoint, not the primary focus, but the consistent 5 to 8 percent body weight reduction across trials established dulaglutide's modest but reliable weight effect.
5%
Weight Loss at Max Dose
At 4.5 mg in AWARD-11 over 52 weeks (T2D patients)
1.5%
Average HbA1c Reduction
AWARD program across multiple trials
5kg
Average Weight Reduction
AWARD-11 vs. 1.5 mg dose comparator
ℹ️ The AWARD trials enrolled type 2 diabetes patients, and weight loss was not the primary endpoint. All participants followed standard of care lifestyle guidance. The AWARD-11 trial specifically tested higher doses (3 mg and 4.5 mg) and produced the strongest weight data for dulaglutide to date. Individual results vary.
"Trulicity doesn't get the press that Ozempic or Zepbound do, and some of that is fair: it does produce less weight loss. But I still see it working well for a specific type of patient, someone who has type 2 diabetes, is needle averse, has tried and tolerated GLP-1s before, and whose insurance will actually cover it. The autoinjector is genuinely easier for a lot of patients than the Ozempic pen. And in diabetic patients who need both blood sugar and weight management, a reliable 5 to 8 percent reduction over a year is real clinical progress, not nothing."
Best suited for T2D patients who want a proven, lower intensity GLP-1 with an easy injection device.Trulicity occupies a specific clinical niche, it's not the strongest GLP-1 drug, but it has a long safety record, a patient friendly injection device, and strong insurance coverage for type 2 diabetes. For the right patient, that combination beats a more powerful drug on paper that's harder to tolerate or afford.
✅ Good Candidates
Type 2 diabetes patients seeking both blood sugar control and moderate weight loss
Patients who are needle averse and want the simplest weekly injection device available
People who previously tried and tolerated GLP-1 drugs without major GI side effects
T2D patients whose insurance covers Trulicity with low out of pocket cost
Those looking for a well established drug with a decade of real world safety data
⚠️ May Not Be Right If...
Weight loss is your primary goal: semaglutide or tirzepatide produce significantly stronger results
You don't have type 2 diabetes and can access Wegovy or Zepbound instead
You have a personal or family history of medullary thyroid carcinoma (MTC)
You have Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
You're pregnant, planning pregnancy, or breastfeeding
You're already on a GLP-1 medication: don't combine GLP-1 drugs
⚕️Always consult your doctor before starting any weight loss medication.
What to Expect
Side Effects
GI side effects are the most common issue, concentrated around dose escalation steps. Most patients get through them.Like all GLP-1 drugs, Trulicity's main side effects are gastrointestinal, nausea, diarrhea, and reduced appetite. These tend to peak during the first few weeks at each new dose level and improve as the body adjusts. Trulicity's GI burden is generally considered comparable to other GLP-1 drugs at equivalent efficacy levels.
Common Side Effects
Usually mild to moderate · Often improve with time
Nausea13%
Diarrhea12%
Abdominal pain9%
Decreased appetite8%
Vomiting8%
Fatigue5%
Serious (Rare) Side Effects
Uncommon · Contact your doctor immediately
Severe abdominal pain (possible pancreatitis)
Thyroid tumors (seen in rodent studies, human risk unclear)
Gallbladder disease or gallstones
Hypoglycemia when combined with insulin or sulfonylureas
Worsening kidney function from dehydration during GI illness
Pricing & Access
What Does Trulicity Cost?
List price is around $900/month, but Lilly savings programs and strong insurance coverage can bring that down substantially.Trulicity has been on the market since 2014, and Eli Lilly's savings infrastructure is mature and well established. For commercially insured patients with a type 2 diabetes diagnosis, coverage is typically strong. The cash pay picture is harder, no generic exists yet.
List Price
$930/mo
Standard pharmacy list price without insurance or savings programs. The actual price varies by dose and pharmacy.
With Lilly Savings Card
$0-25/mo
Eli Lilly's savings card can reduce cost to as low as $0/month for eligible commercially insured patients. Check eligibility at trulicity.com.
No Insurance
High
Cash pay prices without assistance are significant. No generic dulaglutide is currently available. Medicare Part D coverage varies by plan.
💡 Insurance tip: Type 2 diabetes is a diagnosis most commercial insurance plans cover aggressively. If you have T2D and a Lilly savings card, Trulicity is often one of the more affordable weekly GLP-1 options. The coverage story is cleaner than the weight loss specific GLP-1s, which still face more frequent prior authorization denials.
Side by Side
Trulicity vs. Other Options
How Trulicity stacks up against the other leading GLP-1 medications.Trulicity sits at the lower end of the GLP-1 efficacy range for weight loss, but holds its own for blood sugar control and real world tolerability.
Medication
Avg. Weight Loss
Form
Food Restriction
Approved For
💉Trulicity You're here
up to 5%
Weekly Injection
None ✓
Diabetes
💉Ozempic
10-15%
Weekly Injection
None ✓
Diabetes / Off-label
💉Wegovy
15%
Weekly Injection
None ✓
Weight Loss
💉Zepbound
21%
Weekly Injection
None ✓
Weight Loss
Common Questions
Frequently Asked Questions
No, they are different drugs. Trulicity contains dulaglutide, while Ozempic contains semaglutide. Both are weekly GLP-1 receptor agonist injections approved for type 2 diabetes and widely used off-label for weight loss, but they are distinct molecules made by different companies. Eli Lilly makes Trulicity, Novo Nordisk makes Ozempic. The clinical trial data consistently shows semaglutide producing greater weight loss than dulaglutide, though Trulicity has a longer track record of real world use since its 2014 approval.
The AWARD trials showed average weight loss of roughly 5 to 8 percent of body weight at the maximum 4.5 mg dose over 36 to 52 weeks. That's meaningful but notably less than what semaglutide and tirzepatide produce. For someone weighing 220 pounds, that's around 11 to 18 pounds. Individual results depend heavily on diet, exercise, starting weight, and metabolic factors. Trulicity was never positioned as a dedicated weight loss drug, so its clinical program wasn't optimized for that endpoint.
A doctor can prescribe Trulicity off-label for weight loss in patients who don't have diabetes, but most physicians today will reach for Wegovy or Zepbound first. Those medications have weight loss specific FDA approvals and substantially stronger clinical data for that purpose. Trulicity as an off-label weight loss drug is an older pattern from before dedicated weight loss GLP-1s were available. That said, if a patient responds well to dulaglutide and their insurance covers it, continuing with Trulicity is a reasonable clinical decision.
Trulicity starts at 0.75 mg once weekly for four weeks, then increases to 1.5 mg. From there, doses can be escalated in 1.5 mg steps every four weeks based on tolerability and response, up to a maximum of 4.5 mg weekly. The autoinjector pen makes the injection process fairly straightforward: it's a one click mechanism that hides the needle, which many patients find less intimidating than traditional syringes.
Trulicity is an older first generation GLP-1 that produces more modest weight loss than newer options. Ozempic at the weight loss doses consistently outperforms dulaglutide. Zepbound and Mounjaro (tirzepatide) add a GIP mechanism on top of GLP-1 and produce even stronger results. In terms of weight loss efficacy, the ranking is roughly: tirzepatide at the top, then semaglutide, then dulaglutide. Trulicity's advantages are its long real world track record since 2014, its well characterized safety profile, and the simple autoinjector device.
